INDIANAPOLIS, Ind. (ADAMS) – A drugmaker headquartered in Indianapolis is capping the cost insured patients will pay for some insulins.
Eli Lilly says the price for its most commonly prescribed insulin will be cut by 70% starting in September.
However, the company is capping monthly out-of-pocket costs at $35.00 immediately for those not covered by Medicare’s prescription drug program.
The change is expected to provide substantial financial relief for those who need insulin to treat diabetes.
Read more here
